Clinical Trials Logo

Clinical Trial Summary

The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05754450
Study type Interventional
Source AUG Therapeutics
Contact Emily Cooke
Phone 610.254.4201
Email ecooke@avalotx.com
Status Recruiting
Phase Phase 3
Start date April 10, 2023
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Enrolling by invitation NCT06282432 - Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
Recruiting NCT05462587 - A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II Phase 3
Completed NCT01917708 - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Phase 1
Completed NCT01998633 - Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Phase 2